KRASrepresents the first biomarker to be integrated in clinical practice for the treatment of colorectal cancer. However, clinical study design, reproducibility, interpretation and reporting of the clinical data remain important challenges. This Review highlights the clinical application of published prognostic and predictive protein and genomic markers and the possibilities offered by novel adaptive clinical trial designs.
- Sandra Van Schaeybroeck
- Wendy L. Allen
- Patrick G. Johnston